Lead Product(s) : Ertapenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market
Details : Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 05, 2021
Lead Product(s) : Ertapenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ertapenem
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 22, 2014
Lead Product(s) : Ertapenem
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 10, 2011
Lead Product(s) : Ertapenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Invanz
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 06, 2010
Lead Product(s) : Ertapenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ertapenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days
Details : Undisclosed
Product Name : Invanz
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 16, 2010
Lead Product(s) : Ertapenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ertapenem
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of Ertapenem in Beta-lactam Allergic Patients.
Details : Undisclosed
Product Name : Invanz
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 09, 2010
Lead Product(s) : Ertapenem
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ertapenem
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 22, 2010
Lead Product(s) : Ertapenem
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
